Pharm Exec's 2026 Pipeline Report: Next Frontiers in Focus

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

As the biopharma industry navigates the beginnings of 2026, it’s safe to conclude that its development engine is no longer defined predominately by singular breakthroughs. Instead, as the trends illustrate, the more apt description is a convergence—of modalities, technologies, and therapeutic design—that are driving today’s advances in healthcare. Product pipelines, across a range of disease settings, are expanding in breadth and complexity. This, in turn, has raised the need for developers of all sizes, the established and emerging, to differentiate their novel target and treatment pathway pursuits not just on efficacy, but on durability, safety, manufacturability, and ultimately, real-world value and patient outcomes.